GLP RT is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — a mechanism designed to combine incretin signaling with glucagon's effect on energy expenditure. As of 2026, it remains an investigational compound in Phase 3 clinical trials and has not received FDA approval for any indication.
Its triple-agonist mechanism has made it a focal point of current metabolic research, with studies examining its effects on glycemic regulation, energy balance, and weight-related pathways relative to single- and dual-agonist compounds already on the market.
This product is intended strictly for laboratory research use. It is not a drug, dietary supplement, or food product, has not been evaluated or approved by the FDA for any use, and is not for human consumption. Because GLP RT is still under clinical investigation, researchers should note that its safety and efficacy profile in humans remains incomplete.
Every lot is tested by an independent, accredited lab before it's listed — purity, heavy metals, endotoxins, and quantity — with the full Certificate of Analysis published and traceable to that specific lot.
[Identity confirmed on certificate]